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Título: Perfiles de pacientes con patología dual: ¿qué diferencias existen 
entre los que acuden a las unidades de salud mental comunitaria y a los 
centros de tratamiento de drogodependencias? 
Resumen: La atención médica y psicológica de pacientes con patología 
dual es realizada por servicios de salud mental, adicciones, o coordinada. 
No obstante, es elección de los pacientes acudir a uno u otro servicio. Este 
trabajo tiene como objetivo analizar las semejanzas y diferencias de pacien-
tes con patología dual que acuden a estos centros. El estudio se ha realiza-
do con 170 pacientes diagnosticados de patología dual atendidos en el Ser-
vicio Provincial de Drogodependencias de Huelva (SPDH) y Unidades de 
Salud Mental Comunitaria (USMC) de la provincia de Huelva. En el SPDH 
la prevalencia de pacientes con dependencia a heroína y cocaína es mayor 
(35.9% vs 2% en USMC y 16.4% en coordinado). En las USMC se observa 
una mayor prevalencia de pacientes con dependencia a cannabis (41.2% vs 
9.4% en el CTA y 16.4% en coordinado). La odds ratio para pacientes con 
episodios hipomaníacos fue de 2.879 (p < .05) en el SPDH, y de 0.483 (p < 
0.05) para episodios maníacos. Hay una mayor prevalencia de pacientes 
con trastornos psicóticos en las USMC en comparación con el SPDH 
(66% vs 37.5%). Las diferencias detectadas en los perfiles deben ser consi-
deradas en la planificación asistencial de los centros que atienden a estos 
pacientes. 
Palabras clave: patología dual; comorbilidad psiquiátrica; salud mental; 
tratamiento; Trastornos por consumo de sustancias. 
  Abstract: The aim of this study was to analyze and compare the profile of 
dual patients treated in mental health units or drug user services with pa-
tients using both. 
The sample consisted of 170 patients diagnosed with dual pathology, re-
cruited using an accidental sampling technique. Of the sample, 64 were be-
ing treated at Addiction Center of Huelva (ADH), 51 at various Commu-
nity of Mental Health Units (CMHU) in the province of Huelva and 55 
were treated with a coordinated use of both resources.  The patients were 
diagnosed using MINI and PID-5. A higher prevalence of patients with a 
cocaine and heroin dependence profile was observed in the patients treat-
ed in ADH (35.9%, as opposed to 2% in CMHU and 16.4% in the coor-
dinated service). For those patients treated in CMHU there was a higher 
prevalence of profiles related to cannabis dependence (41.2%, as opposed 
to 9.4% in the ADH and 16.4% in the coordinated service). The odds ra-
tio for hypomanic episodes was 2.879 (p < 0.05) for patients in ADH 
compared with the other two services. The odds ratio observed for manic 
episodes was 0.483 (p < .05) in ADH patients, whilst for patients in 
CMHU there was a higher prevalence of comorbid psychotic disorders in 
comparison with those using ADH services (66% as opposed to 37.5%). 
The high prevalence of comorbid disorders -along with the differences in 
profiles identified between services- suggests the need to consider treating 
these patients using integrated services. 
Keywords: Dual disorders; psychiatric comorbidity; mental health; treat-
ment; Substance use disorders. 
 
Introduction 
 
Dual pathology is a research issue that has been widely ad-
dressed by the scientific literature on addiction. In PubMed it 
is observed that the number of articles increases by approx-
imately 200 new publications each year. These include epi-
demiological studies of prevalence (Hasin & Grant, 2015; 
Kessler & Chiu, 2005), nosology of dual pathology (Carmiol 
et al., 2014), effectiveness of intervention modalities (Hob-
den et al., 2018; Najt, Fusar-Poli & Brambilla, 2011), or fac-
tors that affect the therapeutic outcome (Horsfall, Cleary, 
Hunt & Walter, 2009; Wise, Streiner & Gallop, 2017). Alt-
hough prevalence rates differ between studies, the majority 
of reports in the literature indicate that psychiatric comorbid-
ity is not an exception among drug use patients, but instead 
occurs most frequently among this population (Torrens, 
Mestre-Pintó & Domingo-Salvany, 2015). 
From a care perspective, patients with dual pathology 
present a greater diagnostic complexity, poorer therapeutic 
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outcomes, and a higher number of health and social prob-
lems than those patients without such comorbidity (Di Lo-
renzo, Galliani, Ferri, Landi & Guicciardi, 2014). The adopt-
ed therapeutic approach usually involves the mental health 
network and specialized addiction services, used sequentially 
or in parallel (Balhara et al., 2016). In Spain, for example, in 
most of the autonomous communities it is common to find 
protocols for joint action between both services to provide 
dual pathology patients with a coordinated care regime (e.g., 
Elvira, Berrocoso, & Santos, 2007; Dirección General ASis-
tencia Sanitaria, 2012). Specifically, these protocols are based 
on the classification developed by Ries (1992), noting that 
coordinated care between both networks is indicated when 
patients have a mental disorder that is highly complex, and 
whose addiction is difficult to manage. However, there are 
also autonomous communities with integrated care units for 
patients with dual pathology. These patients receive their 
treatments for both disorders by the same therapeutic team.  
Therefore, in organizational terms, these units are more 
adapted to the needs of these patients, increasing the likeli-
hood that they receive consistent diagnoses of their disor-
ders, thereby avoiding contradictory therapeutic indications 
and achieving more efficient therapeutic prescriptions 
(Drake & Mueser, 2000). This modality of care is less wide-
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spread, not only in Spain but also in the rest of Europe and 
North America, in spite of the fact that various studies have 
indicated that this approach could be more effective (Drake, 
Mueser & Brunette, 2007; Georgeson, 2009; Staiger, How-
ard, Thomas, Young & Mccabe, 2014; Staiger, Long & 
Baker, 2010). This is because the creation of these units is 
complex for logistical and economic reasons. 
Following the therapeutic results framework developed 
by Simpson et al. (1997), the effectiveness of the treatments 
depends fundamentally on structural / organizational factors 
of the care services, the type of intervention, and factors re-
lated to the characteristics of the patients. In the case of pa-
tients with dual pathology, a number of studies have ana-
lyzed these factors with the aim of promoting greater inte-
gration between mental health care networks and addiction 
services. For example, in structural / organizational terms it 
has been emphasized that changes in the therapist / patient 
ratio, the number of appointments, the availability of specific 
services, or guidance in the training of professionals 
(McGovern, Lambert-Harris, Gotham, Claus & Xie, 2014; 
Padwa, Guerrero, Braslow & Fenwick, 2015; Priester et al., 
2016; Timko, Dixon & Moos, 2005) could all serve to im-
prove the care of these patients. In terms of the intervention 
used, various authors have shown through review studies 
how there are specific interventions that can be more effec-
tive for patients based on the clinical profiles they present 
(Kelly, Daly & Douaihy, 2012; Torrens et al., 2015). Moreo-
ver, in terms of the characteristics of the patients, there are 
numerous studies comparing profiles of patients with and 
without dual pathology, and the relationship with therapeutic 
outcomes. However, most of these studies have been carried 
out either with patients treated in mental health services 
(Martín-Santos et al., 2006), or with those treated in addic-
tion services (Araos et al., 2014; Carou, Romero & Luengo, 
2017; Gual, 2007; Martínez-Gras et al., 2016; Pereiro, Pino, 
Flórez, Arrojo, & Becoña, 2013; Vergara-Moragues et al., 
2012). These results, although useful, offer limited scope for 
informing care policies adapted to the profiles of the patients 
of each healthcare network. In general, these are independ-
ent studies, carried out at different times and places, so that 
no firm conclusions can be drawn about the most appropri-
ate (i.e. profile-dependent) care policies that should be im-
plemented for dual pathology patients. 
One of the few studies that addressed this issue was that 
conducted by Havassy, Alvidrez, and Owen (2004). These 
authors carried out a study in the United States and used as 
their starting point the hypothesis that for dual pathology pa-
tients, there would be clinical differences between those who 
attended mental health services and those who used special-
ized addiction services. However, these authors found little 
difference between dual pathology patients treated in the two 
care networks. In Spain, the 'Madrid Study' (Arias et al., 
2013a, 2013b, 2013c) was carried out with patients treated in 
the addiction center network and those treated in the mental 
health network. This study revealed differences between the 
care networks in terms of the prevalence of dual pathology 
patients (36.1% in mental health and 70.3% in the addiction 
center network), although no results were presented regard-
ing a comparison of the profiles of these patients. In addi-
tion, there are as yet no clearly defined profiles of those pa-
tients where there are clinical indications for the use of re-
ceiving coordinated care. Therefore, the aim of the present 
work was to provide one of the first national in-depth studies 
of the profiles of patients in which there are indications for 
coordinated care.  In particular, our goal was to compare the 
patients that follow this therapeutic indication with two other 
groups that attend only one of the two centers of the 
healthcare network.  To this end, our two objectives were as 
follows: i) to analyze if there are differences in socio-
demographic characteristics, substance dependence, and psy-
chopathology according to the type of care modality that the 
patients receive; ii) to determine if any of these characteris-
tics could affect attendance to each of these therapeutic mo-
dalities. In terms of a hypothesis, Havassy et al. (2004) found 
little difference between the two networks and, whilst in the 
present work we will study patients in which there are indica-
tions for coordinated care, according to the protocols there 
should be no differences between patients. Thus, it can be 
hypothesized that: 1) there should be no socio-demographic 
differences between patients according to the type of care 
services they attend; 2) the substance dependency profile 
should not differ between patients according to care modali-
ty; and, 3) there should be no differences in terms of other 
mental disorders depending on the type of care. 
 
Method 
 
Participants 
 
The sample frame of the study consisted of patients di-
agnosed with dual pathology and treated in the Community 
Mental Health Units (CMHU) of Huelva and the Provincial 
Service of Drug Addiction of Huelva (ADH). The CMHU 
consists of multidisciplinary teams providing walk-in and 
domiciliary services belonging to the network of specialized 
care centers for people with mental health problems.  The 
ADH is an outpatient treatment center coordinated by a 
multidisciplinary team whose service portfolio is focused on 
preventive care and treatment for people with addiction 
problems. The ADH also fulfills the function of coordinat-
ing all outpatient addiction treatment centers in the province 
of Huelva. To participate in the study, patients had to meet 
the following inclusion criteria: 1) to have a general level of 
functional activity, as evaluated by the Global Activity As-
sessment Scale (EGA) < 50; 2) to have been diagnosed with 
at least one substance dependence disorder in the last year 
according to DSM-IV-TR criteria; 3) to have been diagnosed 
in the last year with at least one other mental disorder with 
severe mental symptoms other than substance dependence 
according to DSM-IV-TR criteria; 4) to have clinical indica-
tions for receiving treatment in the coordinated service be-
tween the CMHU and ADH centers. The exclusion criteria 
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were: 1) to have been diagnosed exclusively with nicotine 
dependence disorder, according to DSM-IV-TR criteria; 2) 
to meet criteria indicating abuse of one or more substances 
according to DSM-IV-TR, without having a diagnosis of de-
pendence; 3) to have been diagnosed with mental retardation 
or another type of disorder that makes the interview impos-
sible; and, 4) not giving signed informed consent. 
Based on these inclusion and exclusion criteria, the care 
coordinators of the CMHU and the ADH prepared a list of 
263 candidate participants. Accidental sampling was used, so 
that all patients who attended their therapeutic appointments 
were invited to participate in the study. The final sample 
consisted of 170 patients (64.6% of the census). Of these, 51 
patients were treated exclusively in the CMHU, 64 patients in 
the ADH and 55 patients were treated in a coordinated 
manner between the CMHU and the ADH. Of the patients 
on the list who did not participate in the study, 25.9% did 
not attend their therapeutic appointment and could not be 
reached, and 9.5% refused to participate in the study. 
 
Instruments 
 
Mini International Neuropsychiatric Interview –MINI- (Sheehan 
et al., 1998). The MINI is a brief diagnostic structured inter-
view, widely used in the field of psychiatry. In this study, the 
Spanish version was used (Ferrando, Bobes, Gilbert, Soto & 
Soto, 2000), through which 16 modules corresponding to the 
main Axis I psychiatric disorders are evaluated. These 16 
modules are evaluated by 82 items, organized as follows: 1) 
Major depressive episode (6 items); 2) Dysthymic disorder (4 
items); Suicide risk (6 items); Manic / hypomanic episode (4 
items); 5) Anxiety disorder (7 items); 6) Agoraphobia (2 
items); 7) Social phobia (4 items); 8) Obsessive-compulsive 
disorder (6 items); 9) Post-traumatic stress disorder (5 items); 
10) Dependence / abuse of alcohol (3 items); 11) Depend-
ence / abuse of other substances; 12) Psychotic disorders (13 
items); 13) Anorexia nervosa (6 items); 14) Bulimia nervosa 
(8 items); 15) Generalized anxiety disorder (3 items); 16) An-
tisocial personality disorder (2 items). Each item presents a 
dichotomous response format that corresponds with the di-
agnostic criteria established in the DSM-IV. 
Several studies have linked the MINI with the Composite 
International Diagnostic Interview (CIDI) and the Structured 
Clinical Interview for DSM-IV Axis II Personality Disorders 
(SCID-II) showing Kappa agreement values between 0.76 
and 0.93 (Lecrubier et al, 1997; Sheehan et al, 1997). In 
terms of internal consistency, values ranging from α = .654 
(obsessive-compulsive disorder) to α = .951 (major depres-
sive disorder) were found in the present sample. 
Personality Inventory for DSM-5-PID-5- (Maples et al., 2015). 
We administered the 100-item Spanish version (Díaz-
Batanero, Ramírez, Domínguez-Salas, Fernández-Calderón 
& Lozano, 2017), which evaluates, through a Likert response 
format ranging between 0 ('Totally false or often false') and 3 
('Very true or often true') the 25 traits included in Section III 
of the DSM-5 (American Psychiatric Association, 2013). The 
score for each trait is obtained by calculating the average of 
the scores of the items. Following Samuel et al. (2013), the 
scores corresponding to scores T <65 of the normative 
scores were considered indicative of clinically significant 
pathological traits. In this study, we used the normative 
scores developed by Gutiérrez et al. (2017). The internal 
consistency for each of the disorders showed values between 
α = .69 (obsessive-compulsive personality disorder) and α = 
.79 (antisocial personality disorder). 
 
Procedure 
 
A psychologist with experience in the evaluation of pa-
tients administered the tests in individual sessions. Before 
starting the data collection period, the psychologist received 
specific training for the administration of these tests.  After 
the therapist had made contact with the patients, the inter-
views were carried out in the centers where the patients re-
ceived their treatment. The therapist also informed the pa-
tients that the study was unrelated to their therapeutic pro-
cess. Initially, the psychologist that administered the tests ex-
plained the objectives of the research and reported the vol-
untary nature of their participation. They were also told that 
the information collected would not be part of their clinical 
history without their express authorization. They were then 
read their informed consent, and if they wished to partici-
pate, they were asked to sign the form. Once the patient had 
given their consent, the interview began. 
The ethics committee of the University of Huelva, and 
the hospital center (to which the Community Mental Health 
Units belong) both approved the study. 
 
Analysis  
 
The socio-demographic variables of the present study 
were analyzed as nominal variables, with the exception of 
age, which is a continuous variable. In the case of diagnoses, 
these are expressed in a dichotomous way, with a value of '0' 
indicating their absence and the value of '1' indicating their 
presence. Initially, a two-stage conglomerate analysis was ap-
plied to identify the profiles according to the main drugs of 
consumption. The Bayesian (Schwarz) criterion was used to 
determine the number of conglomerates, whilst the chi-
square statistic was used to analyze the association between 
categorical variables. An ANOVA was conducted to deter-
mine the relationship between categorical and continuous 
variables. 
Odds ratios were calculated through a logistic regression 
analysis, indicating the probability that an event occurs ver-
sus the probability that it will not occur. In the specific case 
of this study, an odds ratio for a given disorder higher than 1 
would indicate that it is more likely to be observed in the 
reference group with respect to the comparative group. An 
odds ratio below 1 is taken to indicate that the disorder is 
less likely in the reference group with respect to the compar-
ative group, whilst an odds ratio equal to 1 indicates that 
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there is the same probability of observing the disorder in 
both groups. 
Finally, a logistic regression analysis was applied, using 
the stepwise procedure to determine which variables have a 
greater explanatory capacity with respect to the therapeutic 
modality. The variables introduced in the model were those 
that showed a value of p < .05. All the statistical analyzes 
were conducted with the STATA version 14.0. 
 
Results 
 
Profile of consumption and prevalence of mental 
disorders in the sample 
 
Patients with problems of alcohol abuse / dependence 
represented 41.8% of the sample, cannabis 45.9%, cocaine 
45.3%, and heroin 24.1%. The cluster analysis revealed a so-
lution of four clusters (Figure 1): 1) the first was composed 
of 51 patients, of whom 100% had problems of alcohol de-
pendence and 31.4% problems with cannabis. This is, there-
fore, a cluster of patients with alcohol dependence, although 
there are also patients who have problems with cannabis use; 
2) the second cluster is composed of 50 patients, 100% of 
which are cocaine dependent, 40% dependent on alcohol, 
52% on cannabis, and 22% heroin. This cluster represents a 
group of patients with cocaine dependence, which also fre-
quently consumes other drugs. This cluster could thus be re-
garded as one of cocaine-poly-drug patients; 3) the third 
cluster consists of 36 patients exclusively dependent on can-
nabis; and, 4) this final cluster consists of 33 patients of 
which 90.9% are dependent on heroin, and 81.8% dependent 
on cocaine. In Andalusia it is not uncommon to find this 
profile of users, who consume a mixture based on cocaine 
and heroin, often referred to as 'rebujao'. 
 
 
Figure 1. Patient clusters according to drug dependence. 
 
With regard to Axis I disorders, 77.6% of the sample 
presented diagnostic criteria compatible with such a disorder. 
Of these, excluding substance use disorders, the most preva-
lent were anxiety disorders (64.1%). and mood disorders 
(50.6%). The prevalence of patients with lifetime psychotic 
disorder was 52.9% and current psychotic disorder 26.5%, 
whilst 20.6% had antisocial disorder, and 2.4% had an eating 
disorder. Personality disorders were detected in 50% of the 
sample. The most prevalent of these disorders were avoidant 
(30.6%), borderline (28.2%), and schizotypal (24.1%). 
 
Socio-demographic characteristics according to modality of interven-
tion 
 
Table 1 displays the socio-demographic characteristics of 
patients according to the type of care they receive. As can be 
seen, the analysis of gender, age, marital status and level of 
study does not reveal that these characteristics are more like-
ly in certain intervention modalities than others. However, it 
is observed that in the group of patients treated in the ADH 
there is a lower probability of finding patients receiving a 
pension with respect to the other therapeutic modalities. 
Specifically, the probability of finding people who receive a 
pension is 2.14 (1 / 0.468 = 2.14) lower than that observed 
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in the other intervention modalities. With respect to eco-
nomic status, the results show that there is a probability of 
2.04 of finding patients who report an economic deficit in 
the ADH compared with the other modalities. In contrast, 
the group of patients treated at the CMHU are 2.72 (1 / .367 
= 2.72) times less likely to report an economic deficit, and 
2.99 times more likely to report having a stable income. 
 
Table 1. Socio-demographic characteristics according to the service in which they receive care. 
 ADH CMHU Coordinated 
 n (%) Odds ratio ADH1 
vs others 
n (%) Odds ratio CMHU1 
vs others 
n (%) Odds ratio Coordinated1 
vs others 
Gender: Males 51 (79.7) 1.246 (0.564-2.752) 45 (88.2) 0.501 (0.192-1.308) 43 (78.2) 1.410 (0.629-3.161) 
Age (Mean, SD) 43 (10.54) 1.027 (0.998-1.056) 38.4 (12.2) 0.970 (0.941-1.000) 40.9 (10.7) 1.000 (0.972-1.029) 
Civil status 
Married/ in relationship 6 (9.4) 1.365 (0.436-4.278) 7 (13.7) 1.678 (0.517-5.448) 4 (7.3) 0.348 (0.074-1.636) 
Divorced/separated 12 (18.8) 0.935 (0.407-2.149) 8 (15.7) 0.778 (0.305 – 1.981) 12 (21.8) 1.332 (0.575-3.087) 
Single 41 (64.1) 0.683 (0.339-1.376) 36 (70.8) 1.156 (0.530 –2.520) 39 (70.9) 1.342 (0.630-2.856) 
Widower 5 (7.8) - 0  0  
Educational level 
No studies Completed 13 (20.3) 0.710 (0.337-1.498) 14 (27.5) 1.289 (0.609 – 2.729) 14 (25.5) 1.113 (0.529 – 2.343) 
Primary studies 32 (50) 1.409 (0.755-2.630) 24 (47.1) 1.145 (0.593 – 2.212) 20 (36.4) 0.602 (0.311-1.165) 
Secondary studies 18 (28.1) 0.991 (0.497 – 0.976) 12 (23.5) 0.709 (0.333- 1.511) 18 (32.7) 1.378 (0.684-2.777) 
University Studies 1 (1.6) 0.405 (0.044-3.703) 1 (2) 0.575 (0.063-5.275) 3 (5.5) 3.260 (0.529-20.100) 
Employment status 
Employed 7 (10.9) 1.737 (0.580 – 5.203) 5 (9.8) 1.329 (0.422-4.179) 2 (3.6) 0.324 (0.070-1.501) 
Unemployed 35 (54.7) 1.768 (0.945 – 3.309) 18 (35.3) 0.536 (0.272-1.056) 25 (45.5) 0.975 (0.511-1.858) 
Pensioner 22 (34.4) 0.468 (0.246-0.888)* 28 (54.9) 1.680 (0.868-3.253) 28 (50.9) 1.348 (0.708-2.568) 
Income 
Without income 44 (68.8) 2.04 (1.063-3.914)* 21 (41.2) 0.367 (0.188-0.721)** 34 (61.8) 1.245 (0.645-2.402) 
Unstable income 16 (25) 0.706 (0.351-1.418) 19 (37.3) 1.685 (0.837-3.396) 15 (27.3) 0.857 (0.419-1.751) 
Stable income 4 (6.2) 0.349 (0.112-1.088) 11 (21.6) 2.997 (1.182-7.596)* 6 (10.9) 0.816 (0.298-2.234) 
*p < .05;  **p < .01 
1. Value 1 for the interpretation of the odds ratio. 
 
Substance use disorders, other Axis 1 mental disorders, and per-
sonality disorders according to the type of intervention 
 
The distribution of the various mental disorders and the 
odds ratio corresponding to each group are shown in Table 
2. In relation to Axis 1 disorders, it is observed that the 
probability of finding patients with manic episodes is 2.07 (1 
/ 0.483 = 2.07) times lower in the ADH compared with the 
other intervention modalities. In contrast, the probability of 
finding patients with hypomanic episodes is 2.879 times 
higher compared with the other care modalities. ADH pa-
tients are 2.82 times less likely to report lifetime psychotic 
disorders than those in the other care modalities, whilst the 
probability of having a current diagnosis of psychotic disor-
der is 2.41 lower than the other modalities. In contrast, pa-
tients in the CMHU are 2.11 times more likely to have had 
psychotic disorders at some time in their lives. The analysis 
of personality disorders did not reveal any differences in 
terms of prevalence or odds ratios among the three interven-
tion modalities analyzed. 
In relation to the consumption profiles, Table 2 shows 
that ADH patients are 3.82 (1 / 0.262 = 3.82) less likely to 
report problems derived from the exclusive use of cannabis. 
In contrast, there is a 5.39 times greater probability of find-
ing patients with a profile of combined heroin and cocaine 
use. The opposite pattern of results was found in CMHU pa-
tients, where they are 4.85 times more likely to report having 
problems derived from cannabis use alone, and 18.51 times 
less likely to report problems of combined heroin and co-
caine use. 
 
Table 2. Comparison of Axis 1 disorders, personality disorders, and substance use disorders according to the service in which they receive care. 
 ADH CMHU Coordinated 
 n (%) Odds ratio ADH1 
vs others 
n (%) Odds ratio CMHU1 
vs others 
n (%) Odds ratio Coordinadated1 
vs others 
Axis disorder 
 I (current) 
50 (78.1) 1.045 (0.495-2.206) 37 (72.5) 0.667 (0.312-1.428) 45 (81.8) 1.448 (0.646-3.245) 
State disorders 
 Mood disorders (current) 
34 (53.1) 1.176 (0.632-2.191) 22 (43.1) 0.651 (0.336-1.262) 30 (54.5) 1.264 (0.664-2.408) 
Major depression 27 (42.2) 0.951 (0.508-1.782) 21 (41.2) 0.902 (0.463-1.753) 25 (45.5) 1.163 (0.609-2.222) 
Dysthymia 8 (12.5) 1.021 (0.398-2.619) 7 (13.7) 1.193 (0.450-3.157) 6 (10.9) 0.816 (0.298-2.241) 
Manic episodes (lifetime)  15 (23.8) 0.483 (0.248-0.941)* 15 (30.6) 1.305 (0.617-2.764) 21 (38.9) 1.642 (0.801-3.363) 
Manic episodes (current) 2 (3.1) 2.677 (0.230-12.210) 2 (3.9) 2.389 (0.327-17.435) 0 0 
Hypomanic Episodes (lifetime) 15 (23.8) 2.879 (1.234 – 6.685)* 5 (10.2) 0.479 (0.171 – 1.346) 6 (11.1) 0.548 (0.207 – 1.447) 
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 ADH CMHU Coordinated 
 n (%) Odds ratio ADH1 
vs others 
n (%) Odds ratio CMHU1 
vs others 
n (%) Odds ratio Coordinadated1 
vs others 
Hypomanic Episodes  
(Current) 
4 (6.2) 2.289 (0.495-10.575) 0 0 3 (5.5) 1.600 (0.345-7.413) 
Anxiety disorders 44 (68.8) 1.387 (0.719-2.678) 29 (56.9) 0.643 (0.327-1.260) 36 (65.5) 1.090 (0.556-2.137) 
Panic disorders 9 (14.1) 1.171 (0.469-2.917) 7 (13.7) 1.103 (0.420-2.892) 6 (10.9) 0.757 (0.279-2.056) 
Generalized Anxiety 24 (37.5) 1.920 (0.976-3.776) 12 (24) 0.699 (0.328-1.490) 13 (23.6) 0.671 (0.320-1.401) 
Agoraphobia 36 (56.2) 1.554 (0.831-2.901) 21 (41.2) 0.643 (0.328-1.259) 27 (49.1) 1.020 (0.531-1.866) 
Social phobia 10 (15.6) 1.041 (0.441-2.459) 10 (19.6) 1.570 (0.658-3.744) 6 (10.9) 0.581 (0.219 -1.542) 
Obsessive-compulsive disorder 14 (21.9) 1.369 (0.627-2.998) 10 (19.6) 1.076 (0.468-2.471) 8 (14.5) 0.645 (0.269-1.546) 
Post-traumatic stress disorder 13 (20.3) 1.433 (0.638-3.218) 6 (11.8) 0.556 (0.211-1.462) 10 (18.2) 1.122 (0.482-2.610) 
Psychotic disorder (lifetime) 24 (37.5)† 0.354 (0.186-0.674)** 33 (66) 2.111 (1.062-4.196)* 33 (60) 1.5 (0.781 – 2.881) 
Psychotic disorder (current) 11 (17.2) 0.415 (0.193-0.892)* 17 (34) 1.598 (0.778-3.283) 18 (32.7) 1.494 (0.737-3.028) 
Eating disorders 2 (3.1) 1.677 (0.230-12.210) 1 (2) 0.773 (0.078-7.616) 1 (1.8) 0.691 (0.070-6.802) 
       Anorexia 0 - 1 (2%) 1.111 (0.172-7.180) 1 (1.8) 2.408 (0.346-16.768) 
       Bulimia 2 (3.1) 3.354 (0.298-37.764) 0 - 1 (1.8) 1.037 (0.092-11.689) 
Antisocial Disorder 17 (26.6) 1.637 (0.777-3.448) 7 (14) 0.505 (0.205-1.244) 12 (21.8) 1.046 (0.478-2.288) 
Personality disorders 34 (54.8) 1.399 (0.739-2.646) 22 (46.8) 0.849 (0.430-1.677) 24 (46.2) 0.811 (0.418-1.572) 
 Antisocial personality 6 (9.4) 2.637 (0.715-9.733) 2 (3.9) 0.566 (0.116-2.765) 2 (3.6) 0.505 (0.103-2.460) 
 Avoidance 23 (35.9) 1.489 (0.765-2.898) 15 (29.4) 0.923 (0.451-1.891) 14 (25.5) 0.691 (0.336-1.422) 
  Borderline 21 (32.8) 1.428 (0.723-2.822) 13 (25.5) 0.821 (0.327-17.435) 14 (25.5) 0.813 (0.393-1.683) 
  Narcissistic 0 - 2 (3.9) 2.86 (0.359-19.322) 2 (3.6) 2.132 (0.292-15.549) 
  Obsessive-compulsive  5 (7.8) 1.038 (0.324-3.321) 5 (9.8) 1.508 (0.468-4.854) 3 (5.5) 0.606 (0.159-2.295) 
  Schizotypal  14 (21.9) 0.819 (0.392-1.710) 13 (25.5) 1.112 (0.520-2.374) 14 (25.5) 1.113 (0.528-2.342) 
Substance Use Disorder 
Dependence on alcohol & cannabis 17 (26.6) 0.765 (0.384-1.524) 18 (35.3) 1.421 (0.705-2.864) 16 (29.1) 0.973 (0.463-1.896) 
Dependence on heroin, cannabis, 
alcohol, & cocaine 
18 (28.1) 0.905 (0.456-1.794) 11 (21.6) 0.564 (0.261-1.217) 21 (38.2) 1.832 (0.921-3.643) 
Dependence on cannabis 6 (9.4) † 0.262 (0.102-0.671)** 21 (41.2) 4.853 (2.231-10.557)** 9 (16.4) 0.637 (0.276-1.468) 
Dependence on heroin & cocaine  23 (35.9) † 5.385 (2.353-12.320)** 1 (2) 0.054 (0.007-0.410)** 9 (16.4) 0.741 (0.318-1.726) 
† Statistically significant differences between the prevalence of the three intervention models (p < .05); * p < .05; ** p < .01 
1. Value 1 for the interpretation of the odds ratio. 
 
The multivariate analysis reveals that, among the dual pa-
thology patients, attendance to the ADH is primarily ex-
plained by having a profile of heroin and cocaine depend-
ence (odds ratio = 3.307), as well as having presented hypo-
manic episodes (odds ratio = 3.248). However, presenting a 
psychotic disorder is a factor that appears to be linked with 
non-attendance to this type of service (3.59 times less likely). 
Similarly, it is observed that in this resource there is a higher 
probability of patients reporting an economic deficit (odds 
ratio = 2.32), whilst attendance to the CMHU is explained 
mainly by presenting a cannabis dependence profile (odds ra-
tio = 3.454), and is clearly not dependent on heroin and co-
caine use (odds ratio = 7.75). It was also found that patients 
with an economic deficit are less likely to use this resource 
(odds ratio = 2.35) in comparison with the other therapeutic 
modalities (Table 3). 
 
Table 3. Multivariate analysis with explanatory variables according to attendance to the ADH vs. others and CMHU vs. others. 
 Odds ratio Error standard t p Confidence Interval (95%) 
ADH1 vs. others 
(Cons) 0.473 0.181 1.96 0.05 0.224 1.000 
Psychotic disorder (lifetime) 0.278 0.104 3.42 0.001 0.134 0.580 
Hypomanic episodes 3.248 1.705 2.24 0.025 1.161 9.090 
Dependency on heroin & cocaine 3.307 1.397 2.83 0.005 1.445 7.570 
No income 2.320 0.901 2.16 0.030 1.083 4.970 
Pseudo R2 = .144; LR chi2 (3) = 29.27; p =.000 
CMHU1 vs. others 
(Cons) 0.371 0.158 2.32 0.021 0.160 0.859 
Dependency on heroin & cocaine 0.129 0.098 2.67 0.008 0.029 0.579 
Dependency on cannabis 3.454 1.529 2.80 0.005 1.449 8.228 
No income 0.425 0.172 2.11 0.035 0.192 0.939 
Pseudo R2 = .175; LR chi2 (3) = 31.41;  p = .000 
1. Value 1 for interpretation of the odds ratio 
 
Discussion 
 
The objective of this study was to compare the profile of du-
al pathology patients who receive coordinated care in two 
centers (CMHU and ADH) with patients who attend only 
one of the centers, as well as to identify which variables de-
termine whether patients use a particular care resource.  The 
initial hypotheses were based on the fact that, since all dual 
pathology patients should receive coordinated care from the 
ADH and CMHU network, there should be no differences 
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in the patient profile according to the modality of care re-
ceived by the patients. The results of this study partially sup-
port this hypothesis; no differences were observed between 
the three therapeutic modalities in terms of the majority of 
the analyzed disorders, although differences were observed 
in lifetime manic and hypomanic episodes, psychotic disor-
der, and dependence on cannabis and heroin and cocaine. 
Although quantitatively there are relatively few disorders in 
which differences were observed, in qualitative terms these 
disorders determine the profile of patients who come to each 
center and their healthcare needs. 
As noted, among the ADH patients there is a higher 
prevalence of hypomanic episodes, but fewer manic epi-
sodes. This may be due to the fact that hypomanic episodes 
are more strongly linked with substance use, and are there-
fore primarily treated in the ADH. On the other hand, when 
patients are in a manic phase, their psychiatric stabilization is 
necessary, and it is therefore unsurprising to observe a lower 
prevalence of manic episodes in the ADH, with a higher 
odds ratio for these episodes in the coordinated service be-
tween the CMHU and the ADH. 
A higher prevalence of patients with heroin and cocaine 
dependence has also been observed in the ADH, with a re-
sidual of this patient profile in the CMHU. In this regard, it 
should be noted that in the ADH, patients admitted to 
treatment for heroin and cocaine dependence represented 
approximately 20% of the patients who started treatment, 
which clearly determines the profile of patients that are 
shown to use these resources. However, there was an ob-
served high prevalence of these patients in the ADH as op-
posed to the CMHU, despite these being patients with other 
(highly complex) mental disorders.  This could be taken to 
suggest that the problems of these patients have been erro-
neously attributed to substance addiction, without adequately 
assessing the impact of other comorbid mental disorders on 
their daily lives. 
Further, the higher probability of observing patients with 
psychotic disorders in the CMHU was also found in the 
study by Havassy et al. (2004).  This result can be explained 
by the higher complexity of psychiatric care required for 
treating such disorders, and hence the higher rates of attend-
ance to this service. In addition, the association between psy-
chotic disorders and cannabis use has been widely docu-
mented (Radhakrishnan, Wilkinson & D'Souza, 2014). 
Therefore, it is logical to suppose that in the CMHU there 
has been a higher prevalence of patients diagnosed with can-
nabis abuse / dependence. It should be noted that in this 
study, these patients correspond mostly with a young patient 
profile (the average age of these patients in this study is 33 
years (SD = 9.7) compared with the average age of 42.8 (SD 
= 10.9) in the remaining patients), who, possibly due to the 
severity of psychotic symptomatology, are more likely to at-
tend the CMHU — rather than the ADH— as a matter of 
priority. 
Another noteworthy aspect of our results is that econom-
ic status emerged as an explanatory variable for the patients' 
use of a particular service. In particular, more patients with 
no income were observed in the ADH centers than in the 
CMHU. There could be a number of reasons for this obser-
vation. For instance, chronic mental health users with severe 
mental disorders often retire early, which affords them a cer-
tain level of economic stability, whilst in the ADH centers — 
strongly linked with low or marginal economic status— the 
patients are heavily stigmatized. Thus, a user with a normal-
ized socioeconomic status prefers to receive treatment at the 
CMHU (or go to private addiction centers) rather than at-
tend ADH centers. Thus, a variable related to the socioeco-
nomic status could be having an impact on their decision to 
select the most appropriate intervention for their mental 
health status. 
From a therapeutic perspective, the results show that al-
most eight out of ten patients have an Axis 1 disorder whilst 
half have personality disorders, with this set of disorders be-
ing presented in a comorbid manner with substance depend-
ence, regardless of the service that is used to treat them. In 
addition to this, it has been observed that there are differ-
ences in patient profiles between the two networks in spite 
of the fact that all if the patients have been diagnosed with 
dual pathology. Therefore, taken together, we consider that 
this set of findings constitutes sufficient evidence to suggest 
that whilst there is good coordination between the services, 
these patients require integrated care by teams of profession-
als that are specialized in dual pathology, a view that appears 
to be shared by the majority of professionals working in ad-
dictions and mental health (Szerman et al., 2014; Vega et al., 
2015). As long as this is not the case, it is necessary to devel-
op clinical protocols that not only include those aspects of 
the patient profile that indicate coordinated care, but that al-
so consider the main evidence on therapeutic modalities and 
their effectiveness for specific patient profiles. 
Although we believe that the results of this study should 
be considered in the care planning of mental health units and 
addiction centers, we consider it necessary to point out some 
limitations. In particular, it was not possible to contact 35.4% 
of the patients with indications for attending mental health 
services and addiction centers in a coordinated manner. The 
inclusion of such patients could have modified the profile of 
the patients observed in each of the therapeutic modalities 
analyzed. However, we consider it noteworthy that they 
stopped attending treatment; that is, it is precisely this 35.4% 
of patients that failed to attend their therapeutic appoint-
ments. This lack of therapeutic adherence could be the result 
of inadequate adjustment to the needs of these patients, 
which negatively affects their prognosis (Roncero et al., 
2013). In this regard, although it has been widely shown that 
the presence of dual pathology negatively affects therapeutic 
adherence, future studies should analyze whether the failure 
to adapt resources to the needs of dual pathology patients 
could be a key factor in the lack of adherence to treatment 
(Araos et al., 2014). It should also be noted that all patients 
in this study were diagnosed with dual pathology by 
healthcare professionals (ADH and CMHU) following the 
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diagnostic criteria of the DSM-IV-TR, as stipulated in the 
joint action protocol (DGAS, 2012). The disorders analyzed 
in this study were assessed through the MINI and the PID, 
the scores of which are in accord with the diagnostic criteria 
DSM-IV and DSM-5 respectively. Both interviews were fun-
damentally of a screening nature, and used diagnostic criteria 
that were different from those used in the inclusion and ex-
clusion criteria; thus homogenization of the different ver-
sions would be desirable. But to the extent that these inter-
views were applied to all patients regardless of the modality 
of care and administered by the same qualified professional, 
we believe that the sources of error for the comparative 
analysis are fewer than those that would otherwise have been 
observed if the analysis had been conducted on the basis of 
diagnoses (made by different professionals) found in the 
clinical histories of each patient. 
In spite of these limitations, we believe that this study 
provides novel findings that could help to inform the devel-
opment of care resources that are adapted to the therapeutic 
needs of dual pathology patients. Future studies should ana-
lyze how different patient profiles evolve in these therapeutic 
modalities in terms of adherence, quality of life, and patient 
functionality. 
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